RNAZ Transcode Therapeutics, Inc.
Nasdaq · SEC CIK 1829635 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 32 since 2022-02-03, latest 2026-09-11 17:10
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| DEFJ, LLC | 10% | — | — |
Transactions 9
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-05 16:05 | 2026-08-03 | RNAZ | DEFJ, LLC | 10% | C - Cnv Deriv | — | +13.83M | 14.13M | +4,611% | — |
| 2023-10-02 | 2023-09-28 | RNAZ | Fitzgerald Thomas A | CFO, Dir | P - Purchase | $0.51 | +49.4K | 56.3K | +708% | +$25.2K | |
| 2023-10-02 | 2023-09-28 | RNAZ | Dudley Robert Michael | CEO, Dir | P - Purchase | $0.51 | +98.0K | 180.3K | +119% | +$50.0K | |
| M | 2023-06-22 | 2023-06-20+ | RNAZ | Dudley Robert Michael | CEO, Dir | P - Purchase | $2.61 | +18.6K | 70.3K | +36% | +$48.6K |
| A | 2023-06-14 | 2023-06-09 | RNAZ | Dudley Robert Michael | CEO, Dir | P - Purchase | $2.76 | +19.0K | 61.2K | +45% | +$52.4K |
| 2023-06-13 | 2023-06-09 | RNAZ | Dudley Robert Michael | CEO, Dir | P - Purchase | $2.76 | +19.0K | 912.1K | +2% | +$52.4K | |
| 2022-09-16 | 2022-09-14 | RNAZ | Dudley Robert Michael | CEO, Dir, 10% | P - Purchase | $1.15 | +20.0K | 893.1K | +2% | +$23.0K | |
| 2022-06-17 | 2022-06-16 | RNAZ | Fitzgerald Thomas A | CFO, Dir | P - Purchase | $1.27 | +12.0K | 139.4K | +9% | +$15.2K | |
| M | 2022-06-01 | 2022-05-27+ | RNAZ | Dudley Robert Michael | CEO, Dir, 10% | P - Purchase | $1.84 | +30.0K | 873.1K | +4% | +$55.3K |
Purchase Sale Sale after option exercise All abbreviations